The pharmacological management of post-stroke muscle spasticity

Drugs and Aging

Volumn 29, Issue 12, 2012, Pages 941-947

  Bakheit, Abdel Magid O ^a  

^a Moseley Hall Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BOTULINUM TOXIN; CANNABINOID; MUSCLE RELAXANT AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; DYSTONIA; HUMAN; INFANTILE SPASM; NERVE BLOCK; OUTCOME ASSESSMENT; PERIPHERAL NERVE; PRIORITY JOURNAL; SPASTICITY; TREATMENT INDICATION;

HUMANS; MUSCLE HYPERTONIA; STROKE;

EID: 84874587954     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0034-z     Document Type: Article

References (41)

1. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010;257:1067-72.
2. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515-22.
3. Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity - the first year after the event. Stroke. 2010;41:319-24.
4. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p. 485-94.
5. Alexon WH. Signs of muscle thixotropy during human ballistic wrist joint movements. J Appl Physiol. 2005;99:1922-9. (Pubitemid 41547193)
6. Bakheit AMO, Fheodoroff K, Molteni F. Spasticity or reversible hypertonia? J Rehabil Med. 2011;43:556-7.
7. Royal College of Physicians of London, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London: Royal College of Physicians; 2009.
8. Dvir Z, Panturin E, Prop I. The effect of graded effort on the severity of associated reactions in hemiplegic patients. Clin Rehabil. 1996;10:155-8. (Pubitemid 26142691)
9. Rushworth G. The nature and management of spasticity. Proc R Soc Med. 1964;57:29-34.
10. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206-7. (Pubitemid 17026064)
11. Tardieu G, Shentoub S, Delarue R. In search of a technique for measuring spasticity. Revue Neurolique. 1954;91:143-4.
12. Löfvenmark I, Werhagen L, Norrbrink C. Spasticity and bone density after a spinal cord injury. J Rehabil Med. 2009;41:1080-4.
13. Eser P, Frotzler A, Zehnder Y, et al. Assessment of anthropometric, systemic, and lifestyle factors influencing bone status in the legs of spinals cord injured individuals. Osteoporos Int. 2005;16:26-34. (Pubitemid 40193216)
14. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Part I - incidence and predisposing factors. Br Med J. 1976;1:1178-83.
15. Ward AB, Aquilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity - a European consensus statement. J Rehabil Med. 2003;35:98-9. (Pubitemid 36329202)
16. Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, Rousseaux M, Trocello J-M, Uzzan M, Dumarcet N. Drug treatments for spasticity. Ann Phys Rehabil Med. 2009;52:746-56.
17. Pedersen E, Arlien-Søborg P, Mai J. The mode of action of the GABA derivative baclofen in human spasticity. Acta Neurol Scand. 1974;50:665-80.
18. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994;44(Suppl 9):S6-10.
19. Morgan KG, Brayant SH. The mechanism of action of dantrolene sodium. J Pharmacol Exp Ther. 1977;201:138-47. (Pubitemid 8086005)
20. Nielsen JF, Hansen HJ, Sunde N, et al. Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg. 2002;104:142-5. (Pubitemid 34262654)
21. The British Medical Association and The Royal Pharmaceutical Society of Great Britain. British National Formulary (March 2012). London: BMJ Group and Pharmaceutical Press; 2012.
22. Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57:451-62. (Pubitemid 34477042)
23. Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30:1230-2.
24. Mueller ME, Gruenthal M, Olsen WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78:521-4. (Pubitemid 27212460)
25. Gruenthal M, Mueller ME, Olsen WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686-9. (Pubitemid 27468690)
26. Cutter NC, Scott DD, Johnson JC. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled randomized trial. Arch Phys Med Rehabil. 2000;81:164-9. (Pubitemid 30080673)
27. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized double-blind placebo controlled trial. Neurology. 1996;46:1306-10. (Pubitemid 26159292)
28. Bakheit AMO, Thilmann AF, Ward AB, et al. A randomized double-blind placebo-controlled dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke. Stroke. 2000;31:2402-6.
29. Bakheit AMO, Pittock S, Moore AP, et al. A randomized double-blind placebo-controlled study of the efficacy and safety of botulinum toxin type A (Dysport) in upper limb muscle spasticity in patients with stroke. J Neurol. 2001;8:559-65. (Pubitemid 35015221)
30. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med. 2002;347:395-400. (Pubitemid 34851831)
31. van Campenhout A, Molenaers G. Localization of the motor endplate zone in human skeletal muscles of the lower limb: anatomical guidelines for injection with botulinum toxin. Dev Med Child Neurol. 2011;53:108-19.
32. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90:9-16.
33. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol. 1995;2:17-8.
34. Odergren T, Hjaltasaon H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose of equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6-12. (Pubitemid 28156530)
35. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303-12. (Pubitemid 43201097)
36. Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2005;133:836-8. (Pubitemid 41797231)
37. Bakheit AMO, Ward CD, McLellan DL. Generalised botulism-like syndrome following intramuscular injections of botulinum toxin type A - a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198. (Pubitemid 27090943)
38. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 93-107.
39. Bakheit AMO, Liptrot A, Newoton R, et al. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35:36-9.
40. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-26. (Pubitemid 37410189)
41. Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil. 1996;10:41-4.